Thus, by decreasing renal glucose reabsorption and increasing urinary glucose excretion, SGLT2 inhibitors, such as empagliflozin, reduce hyperglycemia in patients with T2D (329). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.